Connect with us

Technology

Ultima Genomics Major Sequencing Award for Singapore’s National Precision Medicine (NPM) Program Phase III

Published

on

Marks Ultima’s first major win to support a national-scale clinical whole genome sequencing initiativeNPM Phase III will leverage Ultima’s UG200 Platform and recent advancements that enable large-scale applications, including Solaris 2.0 Chemistry, launched in February 2026.Ultima will partner with Lucence, a leading Singapore-based clinical lab offering clinical and oncology applications, and QIAGEN, the leader in technologies enabling end-to-end clinical sequencing workflows

SINGAPORE and FREMONT, Calif., Nov. 2, 2026 /PRNewswire/ — Ultima Genomics, a company offering a new architecture for enabling ultra-high-throughput next generation sequencing, today announced that its UG200 Sequencing Platform has been selected for the SG-INSIGHT study, a cohort under Phase III of Singapore’s National Precision Medicine (NPM) program, a national initiative focused on advancing the integration of genomics into clinical workflows and healthcare delivery. Precision Health Research, Singapore (PRECISE) is the central coordinating office for the NPM program. The award coincides with recent advancements in Ultima’s technology that enable high-quality, large-scale, and low-cost whole genome sequencing, including the launch of Ultima’s UG200 Sequencing Platform and Solaris 2.0 chemistry in February 2026.  Ultima will support the program through a collaboration with Singapore-based Lucence, a Singapore-based precision medicine leader, and QIAGEN, a global leader in Sample to Insight solutions. 

NPM Phase III significantly expands the scale and scope of Singapore’s precision medicine effort to about 450,000 individuals — nearly one in 10 Singapore residents — with a significant shift toward participants receiving medical treatment and healthcare services. Unlike Phase II, which focused on healthy individuals, Phase III includes patients across a wide spectrum of health conditions from Singapore’s three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth. NPM Phase III is intended to generate evidence to support the safe and effective rollout of genetic screening and future integration of genomics into public healthcare.

The selection of Ultima technology as part of the Consortium led by Lucence follows an extensive evaluation process. Throughout the process, Ultima and its consortium partners demonstrated a comprehensive approach that addressed quality, clinical readiness, pricing and innovation using Ultima’s latest technology, including the UG200 system, Solaris 2.0 chemistry, and bioinformatics analytics.  

“This award is an important milestone for Ultima Genomics and demonstrates significant advancements to our platform that unlock whole genome sequencing for clinical applications at scale, at low cost, and with high-quality data.  NPM Phase III’s SG-INSIGHT cohort is an excellent example of how Ultima’s drive towards lower costs can support national-scale precision medicine initiatives across geographies worldwide.  It also shows how the UG200 can enable our customers and partners to support cost-sensitive initiatives,” said Gilad Almogy, Chief Executive Officer of Ultima Genomics. “We are honored to work alongside Lucence and QIAGEN in Singapore and to contribute to a program that is advancing the integration of genomics into healthcare. NPM Phase III’s SG-INSIGHT represents an important opportunity to demonstrate how innovation, collaboration, and operational excellence can accelerate precision medicine at a population scale.”

Under the collaboration, Lucence will provide end-to-end clinical program management and local operational leadership, QIAGEN will support sample preparation and automation workflows, and Ultima will provide sequencing and genomic analysis capabilities designed to enable high-quality, scalable, clinical-grade whole-genome sequencing. Together, the consortium aims to support the successful execution of NPM Phase III and to establish a model for future national genomics initiatives.

The award further strengthens Ultima’s presence in the Asia-Pacific region and underscores the company’s ongoing commitment to advancing population genomics, precision medicine, oncology, rare disease research, and emerging clinical applications across global healthcare systems. SG-INSIGHT is expected to serve as a key reference program as governments, healthcare providers, and research institutions explore broader adoption of precision medicine.

Singapore has established itself as a global leader in biomedical innovation and precision medicine. Through collaboration with local healthcare, research, and industry partners, Ultima aims to contribute to the development of a sustainable genomics ecosystem that supports scientific advancement, clinical innovation, and long-term healthcare impact.

Ultima continues to advance its sequencing and analysis capabilities to support clinical whole genome sequencing at population scale. These efforts include the recent launch of paired-end sequencing and the development of pangenome-aware WGS analysis, which is expected to be available by year-end 2026. Together, these capabilities will expand the flexibility of Ultima’s technology for whole-genome and other large-scale sequencing applications.

https://www.ultimagenomics.com/

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company’s mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.

About Precision Health Research, Singapore (PRECISE)

Precision Health Research, Singapore (PRECISE) leads the National Precision Medicine (NPM) programme, advancing genomics to improve health and grow Singapore’s biomedical sector. Phase II sequenced 100,000 Singaporeans, while Phase III, in partnership with Singapore’s three healthcare clusters, is evaluating how genomics can be integrated into clinical care responsibly. 

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). NPM Phase II is supported by the National Research Foundation, Singapore under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734). 

www.npm.sg

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated benefits from participation in Singapore’s National Precision Medicine Program, the expected impact of the NPM Phase III initiative, future sequencing volumes and program expansion opportunities, advancement of precision medicine, growth opportunities in Asia-Pacific and other regions, development of future collaborations, and potential clinical and commercial applications of Ultima’s technologies. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect actual results include program timelines, regulatory developments, market conditions, clinical validation outcomes, operational execution, technological performance, and other risks associated with the commercialization and adoption of genomic technologies. Ultima Genomics undertakes no obligation to update forward-looking statements except as required by applicable law.

mailto:ir@ultimagenomics.com

Media Contact
Vikki Herrera
Oak Street Communications for Ultima Genomics
vikki@oakstreetcommunications.com
408-206-7009

View original content to download multimedia:https://www.prnewswire.com/news-releases/ultima-genomics-major-sequencing-award-for-singapores-national-precision-medicine-npm-program-phase-iii-302926879.html

SOURCE Ultima Genomics

Continue Reading

Technology

Allooloo Tops 100M Capital Markets AI Agent Traffic a Month

Published

on

By

Agentic datasets on every listed company in 34 countries: sourced, dated and signed.

VANCOUVER, BC and LONDON, Nov. 20, 2026 /PRNewswire/ — Allooloo Technologies Corp. (Allooloo), maker of agentic datasets for capital markets artificial intelligence (AI) agents, today reported 100M AI agent traffic a month. That is 39 calls a second, 3.4 million a day, across getissuer.ai and Issuerwire.ai, running on 24 Microsoft Azure hyperscale locations globally with always-on Amazon Web Services (AWS) redundancy.

The Data Readiness Gap

Investment banks are not short of AI models. They are short of data an AI agent can use. In a 2026 Teradata study, 77% of technology leaders said 20% or less of their enterprise data is ready for AI agents. Banks are closing that gap on the data they hold, with one governed way in and the source, the date and the owner on every record.

The data a bank does not hold is the other half. An AI agent working on a security needs the issuer, its disclosures and whether it may be ordered, in every market the bank trades. Allooloo delivers that half agent-ready: 41.9K listed companies in 34 countries, a source and a date on every field, and a signed receipt for every read, over Model Context Protocol (MCP).

Two Products

Know Your Product (KYP) is the duty to know a security before it is recommended or sold. Allooloo KYP, at getissuer.ai, answers it for the AI agent: who the issuer is, whether it may be ordered, and who it is for. It covers 41.9K listed companies on 79 exchanges in 34 countries.

Issuerwire.ai is the dated disclosure wire: 3.1 million dated disclosures across 34 countries, each with its source.

Who it matters to:

Investment bank or dealer: its AI agents can show where each fact came from.The issuer: every AI agent reads the same answer about it.Compliance: a signed receipt for every cleared read.

A Signed Receipt for Every Read

Every cleared read on Allooloo leaves a signed receipt, the Record of Cleared Orders (RCO): what was read, when, and under which market’s rules.

Each Market in Its Own Country

Each market is kept in its own country or region, across 24 Microsoft Azure regions, on one MCP server per market. A second copy of every market is made each night on AWS and locked against deletion for 365 days. Allooloo is a Microsoft AI Cloud Partner.

Around the Clock

The products are made around the clock by Allooloo’s own team and AI agents, on the Allooloo Algo. AI agents call them around the clock and pay per call, with no seat and no licence.

“Today we are announcing a milestone: 100M AI agent traffic a month,” said Matthew Keddy, Chief Executive Officer of Allooloo Technologies Corp. “These are the AI agents of capital markets participants, and they want crisp data, five years deep, on 41.9K listed companies across 79 exchanges: sourced, dated and signed. Gain the edge with us.”

In Session and Enterprise Grade

Allooloo is sold two ways. In session, an AI agent calls Allooloo mid-task and pays as it goes (PayGo) on x402, the open payment standard for AI agents, with no seat and no licence. At enterprise grade, a firm licenses the datasets to design, build and run its own AI agents.

About Allooloo Technologies Corp.

Allooloo Technologies Corp. makes agentic capital markets data products for the AI agents of banks, dealers and issuers. Its products, getissuer.ai and Issuerwire.ai, cover 41.9K listed companies on 79 exchanges in 34 countries, kept across 24 Microsoft Azure regions with on-the-fly redundancy on Amazon Web Services (AWS). The result is always-on agentic datasets: in session for AI lab users, and enterprise grade for customers who design, build and run their own AI agents. Allooloo is headquartered in Vancouver, Canada. Please visit: allooloo.ai 

View original content:https://www.prnewswire.com/news-releases/allooloo-tops-100m-capital-markets-ai-agent-traffic-a-month-302947422.html

SOURCE Allooloo Technologies Corp.

Continue Reading

Technology

Allooloo Tops 100M Capital Markets AI Agent Traffic a Month

Published

on

By

Agentic datasets on every listed company in 34 countries: sourced, dated and signed.

VANCOUVER, BC and LONDON, Nov. 21, 2026 /PRNewswire/ — Allooloo Technologies Corp. (Allooloo), maker of agentic datasets for capital markets artificial intelligence (AI) agents, today reported 100M AI agent traffic a month. That is 39 calls a second, 3.4 million a day, across getissuer.ai and Issuerwire.ai, running on 24 Microsoft Azure hyperscale locations globally with always-on Amazon Web Services (AWS) redundancy.

The Data Readiness Gap

Investment banks are not short of AI models. They are short of data an AI agent can use. In a 2026 Teradata study, 77% of technology leaders said 20% or less of their enterprise data is ready for AI agents. Banks are closing that gap on the data they hold, with one governed way in and the source, the date and the owner on every record.

The data a bank does not hold is the other half. An AI agent working on a security needs the issuer, its disclosures and whether it may be ordered, in every market the bank trades. Allooloo delivers that half agent-ready: 41.9K listed companies in 34 countries, a source and a date on every field, and a signed receipt for every read, over Model Context Protocol (MCP).

Two Products

Know Your Product (KYP) is the duty to know a security before it is recommended or sold. Allooloo KYP, at getissuer.ai, answers it for the AI agent: who the issuer is, whether it may be ordered, and who it is for. It covers 41.9K listed companies on 79 exchanges in 34 countries.

Issuerwire.ai is the dated disclosure wire: 3.1 million dated disclosures across 34 countries, each with its source.

Who it matters to:

Investment bank or dealer: its AI agents can show where each fact came from.The issuer: every AI agent reads the same answer about it.Compliance: a signed receipt for every cleared read.

A Signed Receipt for Every Read

Every cleared read on Allooloo leaves a signed receipt, the Record of Cleared Orders (RCO): what was read, when, and under which market’s rules.

Each Market in Its Own Country

Each market is kept in its own country or region, across 24 Microsoft Azure regions, on one MCP server per market. A second copy of every market is made each night on AWS and locked against deletion for 365 days. Allooloo is a Microsoft AI Cloud Partner.

Around the Clock

The products are made around the clock by Allooloo’s own team and AI agents, on the Allooloo Algo. AI agents call them around the clock and pay per call, with no seat and no licence.

“Today we are announcing a milestone: 100M AI agent traffic a month,” said Matthew Keddy, Chief Executive Officer of Allooloo Technologies Corp. “These are the AI agents of capital markets participants, and they want crisp data, five years deep, on 41.9K listed companies across 79 exchanges: sourced, dated and signed. Gain the edge with us.”

In Session and Enterprise Grade

Allooloo is sold two ways. In session, an AI agent calls Allooloo mid-task and pays as it goes (PayGo) on x402, the open payment standard for AI agents, with no seat and no licence. At enterprise grade, a firm licenses the datasets to design, build and run its own AI agents.

About Allooloo Technologies Corp.

Allooloo Technologies Corp. makes agentic capital markets data products for the AI agents of banks, dealers and issuers. Its products, getissuer.ai and Issuerwire.ai, cover 41.9K listed companies on 79 exchanges in 34 countries, kept across 24 Microsoft Azure regions with on-the-fly redundancy on Amazon Web Services (AWS). The result is always-on agentic datasets: in session for AI lab users, and enterprise grade for customers who design, build and run their own AI agents. Allooloo is headquartered in Vancouver, Canada. Please visit: allooloo.ai 

Contact: Matthew Keddy, CEO. mk@allooloo.ai +1 647 237 7744

View original content:https://www.prnewswire.com/apac/news-releases/allooloo-tops-100m-capital-markets-ai-agent-traffic-a-month-302947427.html

SOURCE Allooloo Technologies Corp.

Continue Reading

Technology

Ziehm-Orthoscan Announces Executive Leadership Transition Following 18 Years of Significant Growth

Published

on

By

Ziehm-Orthoscan Announces CEO Transition and Executive Leadership Appointments

SCOTTSDALE, Ariz., Nov. 20, 2026 /PRNewswire-PRWeb/ — Ziehm-Orthoscan Inc., the leader in mobile C-arm imaging solutions, today announced an executive leadership transition as President and Chief Executive Officer Nelson Mendes prepares to step down on December 31, 2026, following 18 years of distinguished leadership.

Effective January 1, 2027, Travis Prikryl will assume the role of Chief Executive Officer, and Hogie Saunders will be appointed Chief Operating Officer. Both executives will also serve as Managing Directors of Ziehm-Orthoscan Inc.

Under Mendes’ leadership, Ziehm-Orthoscan experienced extraordinary growth and transformation, evolving from a small U.S. operation into a major contributor to the company’s global business. Since 2009, U.S. operations have grown from approximately six employees to nearly 200, reflecting Ziehm-Orthoscan’s significant expansion and continued investment. This growth includes the establishment of a new headquarters and production facility in Scottsdale, Arizona, which serves as the global center for the development and manufacturing of all Orthoscan mini C-arm systems.

A significant milestone in this transformation was the acquisition and integration of Orthoscan in 2015, bringing together Ziehm’s full-size mobile C-arm technology and Orthoscan’s mini C-arm expertise. This strategic expansion established a comprehensive mobile imaging portfolio, strengthened the company’s competitive position, and accelerated its growth throughout the U.S. healthcare market.

Throughout his tenure, Mendes championed innovation, operational excellence, and customer relationships, helping establish Ziehm-Orthoscan as a trusted imaging partner to healthcare institutions nationwide.

To ensure a seamless transition, Mendes will remain with the company as a full-time strategic advisor through March 31, 2027, followed by a part-time consulting role supporting the organization’s continued development.

The appointments of Travis Prikryl and Hogie Saunders represent the next chapter in Ziehm-Orthoscan’s long-term growth strategy. Together with the company’s experienced management team, they will focus on advancing imaging innovation, strengthening customer partnerships, expanding market opportunities, and building on the strong foundation established over the past 18 years.

Ziehm-Orthoscan extends its sincere appreciation to Nelson Mendes for his exceptional leadership and contributions while expressing full confidence in the incoming executive team to guide the organization into its next phase of growth and success.

About Ziehm-Orthoscan

Ziehm-Orthoscan is the leader of innovative mobile imaging solutions, combining Ziehm’s expertise in full-size mobile C-arms with Orthoscan’s specialized mini C-arm technology. The company is committed to advancing medical imaging through innovation, exceptional service, and solutions designed to meet the evolving needs of healthcare professionals.

Media Contact

Rich Shaul, Vice President Marketing, Ziehm-Orthoscan, Inc., 1 4805038010, marketing@ziehm-orthoscan.com, https://ziehm-orthoscan.com/

View original content to download multimedia:https://www.prweb.com/releases/ziehm-orthoscan-announces-executive-leadership-transition-following-18-years-of-significant-growth-302946604.html

SOURCE Ziehm-Orthoscan, Inc.

Continue Reading

Trending